x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Cancer is a fascinatingbut rapidly evolvingdiscipline- it"s a full-time job just keeping up to date. In this podcast,Dr Michael Fernando and Dr Joshua Hurwitz explorethe latest trials, research, and practice-changing updates,as well asregular interviews with renowned oncology specialists.Ideal for thosestarting their trainingjourney, established specialistsandanyone interested in medical science, oncological practice,or terrible jokes. Preferably all three. Hosted on Acast. See acast.com/privacy for

health & fitness medicine

All Episodes

35:58

82. Metastatic triple negative breast cancer (TNBC)

Oncology for the Inquisitive Mind ·

2023/12/16

Oncology for the Inquisitive Mind would like to issue a formal mae culpa to our listeners. You have joined us for over 12 months and over 80 episodes and listened to our ramblings and bad jokes. And it has taken 80 episodes for us to realise we have neglected the crucial and exciting subject of metastatic triple-negative breast cancer (TNBC). But fear not! We will rectify this egregious oversight with immediate effect. TNBC remains the scourge of the usually more optimistic breast cancer space

en

22:24

Fireside Chats 2. Time Toxicity in Early Phase Trials

Oncology for the Inquisitive Mind ·

2023/12/12

For patients with advanced cancer, early-phase trials may represent the last best hope of significant anticancer response. For clinicians, every early phase trial holds virtually unlimited promise and hope of becoming the next immunotherapy or hot antibody-drug conjugate. However, early-phase trials also come with significant uncertainty of efficacy, toxicity and even dosing.A recent Limbic article (link below) reported on an article published in ESMO Open that investigated the burden of "time

en

29:55

81. San Antonio Breast Cancer Symposium Update

Oncology for the Inquisitive Mind ·

2023/12/09

San Antonio Breast Cancer Symposium is here, and this year, OFTIM (Oncology for the Inquisitive Mind) is bringing you the latest and greatest in all things breast cancer. With over 10000 attendees, the research and vibrant discussions did not disappoint, with updates, controversies and complexities. Taking centre stage were PIK3CA mutation treatments, updates on CDK4/6 inhibitors and the age-old question - does exercise improve outcomes for our patients?Studies discussed in today's episode

en

30:54

80. ESMO 2023 - Plenary Session

Oncology for the Inquisitive Mind ·

2023/11/07

Today, OFTIM celebrates its 80th episode and presents its ESMO23 plenary session, including two practice-changing, paradigm-shifting trials. The first investigates the EGFR mutation Non-Small Cell Lung Cancer world with new drugs (amivantamab and lazertinib) to treat patients hose who progressed on osimertinib. The second trial is the EV-302/KEYNOTE-A39, which explores whether enfortumab vedotin (ADC) and pembrolizumab (immunotherapy) can best-platinum-based chemotherapy. No prior trial has ever

en

23:21

79. ESMO 2023 - Gynaecological Oncology

Oncology for the Inquisitive Mind ·

2023/11/06

As Oncology for the Inquisitive Mind's coverage of ESMO 2023 winds down, we bring some of the best presentations covering gynaecological cancer. An area of oncology that in many cases remains mired in the pre-immunotherapy and pre-targeted therapy ages, ESMO brought some much-needed positive trials in the areas of cervical cancer, as well as an interesting (albeit negative) study of the PARP-inhibitor olaparib that highlights some of the more practical challenges of running an international phase 3

en

23:12

78. ESMO 2023 - Skin Cancer and Melanoma

Oncology for the Inquisitive Mind ·

2023/11/05

Since the early development of immunotherapy, metastatic melanoma has been the golden child of medical oncology. In recent years, similar outcomes have been seen with immunotherapy in non-melanomatous skin cancers. Cemiplimab is now a standard of care for patients with locally advanced, unresectable or metastatic cSCC, and is particularly effective in patients with cancer driven by UV-induced DNA damage. However, oncologists and researchers are always looking for new and better ways to use

en

32:26

77. ESMO 2023 - Non Small Cell Lung Cancer

Oncology for the Inquisitive Mind ·

2023/11/02

Non-small cell lung cancer continues to show massive promise with new trials, better designs and exciting utilisation of existing therapies. Michael and Josh explore immunotherapy in a "sandwich setting" where nivolumab is given before and after surgery. Datopotamab deruxtecan, the new kid on the block, takes on the second-line champion docetaxel. Who will win, and will docetaxel finally be dethroned? And potentially the most promising and exciting addition to this lineup is AZD7789, a new

en

23:11

76. ESMO 2023 - Colorectal Cancer (Part 2)

Oncology for the Inquisitive Mind ·

2023/11/01

Metastatic colorectal cancer has an average overall survival of three years. With limited treatment options as standard of care or effective targetable mutations, ESMO23 shined, providing answers to unanswered questions and a potentially brighter future for this cancer. Concerningly, we are seeing higher rates of colorectal cancer in lower and middle-income countries and those under the age of 50. We explore sotorasib in KRASG12C mutated cancers with panitumumab, the use of aspirin to reduce the

en

22:44

75. ESMO 2023 - Colorectal Cancer (Part 1)

Oncology for the Inquisitive Mind ·

2023/10/31

Colorectal cancer remains the bread and butter of many an oncologist, but its commonality belies its complexity. In early and advanced disease alike, there remain many permutations, considerations and controversies regarding optimal treatment. What is the best way to treat potentially-resectable colorectal cancer with liver metastases (CRLM)? Is there a way to increase the responsiveness to immunotherapy in patients with proficient mismatch repair (pMMR)? And are we moving to a brighter future where

en

24:48

74. ESMO 2023 - Upper GI and Hepatobiliary Cancer

Oncology for the Inquisitive Mind ·

2023/10/30

Next up on the ESMO 2023 rollercoaster is an episode that is likely to be the shortest in our series: upper gastrointestinal and hepatobiliary oncology. As always, this remains a very challenging subarea of medical oncology, both in the clinical and trial spheres. However, our esteemed colleagues at ESMO remain undaunted by this challenge, and thus several studies of interest bear discussing. Will any of these studies lead to massive upheavals for clinicians and patients alike? For that answer,

en

27:13

73. ESMO 2023 - Genitourinary Cancers - Prostate and...

Oncology for the Inquisitive Mind ·

2023/10/30

Genitourinary cancers come in all shapes and sizes, and this year, ESMO2023 takes the research up a notch. Prostate cancer is centre stage, and you might ask why, as it boasts extraordinary overall survival and progression-free survival. The issue lies in the sequencing of therapies and how to make treatment durable and better tolerated for all. Third, immunotherapy is not ready for primetime in this cohort of patients, and the reasons are unclear. Not to be outdone, bladder cancer continues to make

en

31:40

72. ESMO 2023 - Early Breast Cancer (Part 2)

Oncology for the Inquisitive Mind ·

2023/10/27

Welcome back to Oncology for the Inquisitive Mind's ongoing coverage of ESMO 2023. In the spirit of a worldwide oncology conference, here we present results from three very exciting trials in the early breast phase. Will immunotherapy begin to carve out a niche in early, high-risk, ER-positive breast cancer? Can atezolizumab demonstrate a benefit in early TNBC, and expand its own territory? Is abemaciclib pulling away from its rivals in the treatment of high-risk, ER-positive breast cancer? Will

en

24:04

71. ESMO 2023 - Early Breast Cancer (Part 1)

Oncology for the Inquisitive Mind ·

2023/10/25

Every so often, an area of medical oncology has so many interesting presentations at a seminal conference that it becomes impossible to leave them out. At such times, Josh and Michael merely shrug their shoulders and say "why don't we do all of them." ESMO 2023 is one such instance. Despite their best efforts, our intrepid duo were unable to narrow down their presentation of early breast cancer highlights to one episode, so they are going to do two (for the price of one).Articles discussed in this

en

19:33

70. ESMO 2023 - Small Cell Lung Cancer

Oncology for the Inquisitive Mind ·

2023/10/24

ESMO 2023 showcased several promising trials in the small-cell lung cancer space. A cancer that continues to send shivers down the spine of budding oncologists for decades. Today, we look at several different classes of drugs, the first being a novel immunotherapy agent, the second a well-known antibody-drug conjugate and the third a synthetic alkaloid analogue. Lurbinectedin and pembrolizumab, sacitizumab govitecan or toripalimab, while all difficult to say five times fast, may change the future of

en

31:49

69. ESMO 2023 - Metastatic Breast Cancer

Oncology for the Inquisitive Mind ·

2023/10/24

Michael and Josh continue their examination of the crème-de-la-crème of the European Society of Medical Oncology conference of 2023. Today they focus on metastatic breast cancer, with a particular focus on antibody-drug conjugates (ADCs). T-Dxd, Dato-Dxd and trastuzumab duocarmazine are just three of the many novel agents in this space, and likely represent part of the future (and the present) of medical oncology. How effective are these treatments? Will the final results of the TULIP study blossom

en

28:14

68. ESMO 2023 - Central Nervous System Tumors

Oncology for the Inquisitive Mind ·

2023/10/22

Another year, another international oncology conference in a beautiful European locale. In 2023, the world's oncology community has descended on the Spanish capital Madrid to discuss the latest and greatest scientific developments in Medical Oncology. And as always seems to be the case, Michael and Josh remain at home listening to this avalanche of information virtually. Despite a distinct lack of sun and Español, our intrepid duo will continue a grand tradition that dates back to 2022: bringing

en

24:31

67. Spotlight: Head and Neck Cancer: Docetaxel as a...

Oncology for the Inquisitive Mind ·

2023/10/14

Cisplatin is the mainstay for concurrent chemoradiotherapy in Locally Advanced Head and Neck Cancers. What happens to that significant group of patients who cannot have cisplatin? Michael and Josh focus on this challenging subgroup of patients. Can docetaxel be used as an alternative? This week, they debut a small but significant segment of our humble podcast called "Spotlight", where we dive deep into a single potentially practice-changing trial. Enjoy!Links to studies discussed in this episode

en

23:32

OncoSnacks 11: Pulmonary Embolism & Deep Vein...

Oncology for the Inquisitive Mind ·

2023/10/11

Cancer inherently increases the risk of Deep Vein Thrombosis and Pumlmonary Embolism. This is merely a nuisance for some, while others experience significant morbidity, leading to hemodynamic instability and potential death. Historically known as "the great masquerader" with pulmonary embolisms, we explore signs, symptoms, and different approaches to treatment. Warfarin remains the original and is still an option for patients, but have better therapies emerged like direct oral anticoagulants

en

44:20

66. Gynae-Oncology with Dr Vish Boolell

Oncology for the Inquisitive Mind ·

2023/10/07

Gynaecological malignancies are a diverse group of terrible malignancies. From ovarian to endometrial to cervical, these cancers are notorious not just for their mortality burden, but the significant morbidity that they can inflict. To explore how to combat these challenging clinical entities, Michael and Josh interview Dr Vish Boolell, a clinical oncologist who brings his vast practical and trial experience to bear in exploring how to best treat patients and manage the myriad challenges

en

35:35

65. Meredith Cummins - CEO of Neuroendocrine Cancer...

Oncology for the Inquisitive Mind ·

2023/09/30

It is frequently said that it takes a village to treat a patient with cancer. However, beyond the nuts and bolts of medical and allied health treatment, there exists a whole other world of advocacy and education. Charitable and not-for-profit foundations, both nationally and internationally, have done incredible work for many years in raising awareness and funding for cancer treatment and prevention, as well as providing both patient- and doctor-centred education. Oncology for the Inquisitive Mind

en

195 results

Similar Podcasts

Доктор Тройняшкин

Доктор Тройняшкин

Podcasts Archives - Extreme Health Radio

Justin Stellman

Oncology for the Inquisitive Mind

Michael Fernando and Josh Hurwitz

Good Sleep: Positive Affirmations

Optimal Living Daily | Sleepy Meditation

Johannes Hansen Podcast

Johannes Hansen